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 Summary
   Mastopathy (mastopathia fibroso-cystica) and breast cancer are two major epidemiologic, economic 
and medical problems of women. In Poland, annually, 0.2-1.6 billion Polish zlotys is spent on 
diagnosis and treatment of mastopathy; half of that sum is spent improperly. Many papers suggest 
relationships between these two diseases, however, it is not certain, whether, or how much, 
mastopathy increases breast cancer incidence. The available papers from the recent years indicate 
increased risk, but the methodology of these data is not perfect. It is not excluded that fibrocystic 
diseases of the breast increase breast cancer incidence. If such an influence exists, independent 
of other well-know factors, it is probably very small. Moreover, due to the diversity of medical 
information there is a lack of diagnostic and therapeutic standards in mastopathy. Different types 
of scans, hormonal, biochemical and immunohistochemical examinations are performed improperly, 
and there has been no genetic analysis of mastopathy. Therefore, there is a strong need of well-
planned, prospective trials in this field. 
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Terminology
Mastopathy is a medical term very frequently encountered 
by doctors and female patient. A “key word” intended to 
facilitate the communication between the doctor and the 
patient, which, however, often makes it more difficult. So, 
what is mastopathy? If we type in this word in the most 
popular web browser service (www.google.pl), we get 645 
Polish websites containing this term. We can read there, 
among others, that:
„Mastopathy, degenerative changes in the tissue of mam-
mary glands, due to hormonal disorders. They usually take 
the form of nodules or indurations, which always require 
specialist control and diagnostic examinations (USG, mam-
mography, biopsy) to be differentiated from malignant 
lesions” [1];
„The first step after detection of cyst-like lesions, which fre-
quently result from chronic hormonal disorders, is  testing 
blood hormone levels, especially those of ovarian hormones 
(estradiol, progesterone, testosterone), pituitary hormones 
(prolactin, luteotropic hormone follicle stimulating hor-
mone) thyroid ones.” [2];
„It should be remembered that mastopahy can increase the 
risk of breast cancer and that breast cancer can develop 
among mastopathic lesions. It should be remembered that a 
tumor may arise both from small cyst-like lesions and from 
large cysts!” [3];
„As a rule, cysts develop in women above 30 years of age, 
very often immediately before menopause. They rarely 
develop in postmenopausal period and in very young women. 
Fine needle biopsy is necessary to confirm the diagnosis” [4];
„Wearing bras is not necessary, and even contraindicated. 
Bras impair vascular function, especially that of lymphatic 
vessels within the breasts, which may lead to an increased 
risk of breast cancer” [5];
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„USG can detect, for example, benign pathologic changes 
in the bust (mastopathy). Such mastopathy, with no malig-
nant lesions, occurs especially in young women. The causes 
may be varied: familial predisposition, hormonal disorders, 
changes in breast tissue caused by premature suppression 
of lactation, or inflammatory conditions of the breast” [6].
The above examples illustrate how many misunderstand-
ings (and even inappropriate actions) may be caused by 
such information.
If we, in turn, type in the English word (mastopathy) in 
the most popular professional medical browser www.
pubmed [7], only 72 medical publications from the recent 
decade containing this word in the title are displayed. 
During that period, 60 papers concerning diabetic mas-
topathy were published, and only 12 concerning fibrocystic 
breast mastopathy, including only 1 publication written in 
English. It is worth remembering that diabetic mastopa-
thy is a rare glandular hyperplasia of fibrous breast tissue, 
which develops in the course of long-lasting type I diabetes. 
Does that mean that mastopathy is a term used (in medi-
cal or popular scientific publications) only in Poland or in 
East Europe? This is probably the case, because English 
scientific literature more often uses the term “benign 
breast diseases” (BBD). However, the meaning of these 
two terms is not identical. Mastopatia fibroso-cystica, as 
indicated by the term itself, may contain fibrous, inflam-
matory and cystic elements, and that is why a synonym 
“fibrocystic degeneration” is often used. According to some 
Polish pathologists, the lesions of hyperplasia nonatypica, 
adenosis (nonsclerosing) and ductectasia may also be com-
ponents of mastopathy. On the other hand, the College of 
American Pathologists (CAP) lists the following pathologic 
conditions, which can be collectively referred to as BBD [8]. 
The College specifies also which of these conditions, and 
to which extent, increases the risk of breast cancer (BC) 
– tab. 1.
It seems that this important table could conclude the pres-
ent considerations, but…. .
Epidemiology and economics
All physicians dealing with breast diseases know that mas-
topathy and BBD are very frequent. Although there are no 
precise epidemiological data, many publications contain 
information that benign lesions of various type are found 
in 30–50% of women. On the other hand, autopsy studies 
indicate that cysts and cyst-like lesions are found in 75% of 
autopsied women. In my opinion, the problem of mastopa-
thy and BBD concerns all women and is of more qualita-
tive than quantitative. Some pathology would probably be 
found in every woman on thorough pathological examina-
tion of the breasts. Similarly, there are no subjects without 
any pathology of the skin.
The lack of epidemiological data from screening tests 
makes it necessary to use various simulations. On the 
basis of a large-scale study conducted in the group of 
265,402 women working in Shanghai clothing industry, 
we know that symptomatic (clinically palpable) fibroad-
enomas frequency amounts to 600/1,000,000 examined 
women. On the basis of that [9] and other studies, the risk 
of developing a fibroadenoma during the whole life can 
be estimated at 5% to 30%. According to another paper, 
based on the analysis of 11,307 women, the incidence of 
category 1 and 2 BBD (tab.1) was determined at 12.2% of 
female population. In that study, fibroadenomas account-
ed for 12% of lesions presenting as a tumor or indura-
tion, so, combining the above data, it can be assumed 
that the frequency of various indurations amounts to 5% 
(annually).
In addition to estimation of the epidemiological data, the 
economic aspect of the problem is also worth  considering. 
Out of 20 m women in Poland, 10% to 20% undergoes 
breast examinations of various type. If expenses of 
Table 1.  Benign breast diseases (BBD) and the risk of breast cancer according to the College of American Pathologists.
Category Breast cancer risk level Pathology 
1 
 
 
 
 
 
Not increased 
 
 
 
 
 
 
 
Adenosis (other than sclerosing adenosis) 
Ductectasia 
Fibroadenoma 
Fibrosis 
Mastitis 
Mild non-atypical hyperplasia 
Simple micro- or macro-cyst 
Simple apocrine metaplasia 
Planoepithelial metaplasia  
2
 
 
 
Slightly increased
 
 
 
Fibroadenoma (with coincident so-called complex features) 
Moderate/extensive non-atypical hyperplasia 
Sclerosing adenosis 
Papilloma without atypical hyperplasia 
3
 
Moderately increased Atypical ductal hyperplasia 
Atypical lobular hyperplasia 
4 
 
Significantly increased
 
Ductal carcinoma in situ 
Lobular carcinoma in situ  
34
Pol J Radiol, 2007; 72(3): 32-36Review Article
 diagnostics in each individual case (clinical examina-
tion, USG, mammography, biopsy, hormonal investiga-
tions and other tests) fall, on the average, within PLN 
100–400 range (payable from all sources) it can be pre-
sumed that annual expenses reach about a billion zlotys 
(range from 200 m to 1.6 bn). It is the amount compa-
rable to the annual budget of all the oncology centers 
in Poland. 
Risk factors for breast cancer
So-called classic breast cancer risk factors [10], in Gail 
model applicable since 1989, include:
• early menarche
• late menopause
• late first pregnancy (childbirth)
• familial occurrence of breast cancer
•  previous biopsies or surgical procedures performed on 
the breast
In 2006, the US National Cancer Institute (NCI) added new 
parameters associated primarily with introduction of mass 
scale mammographic screening [11, 12]:
• high mammographic breast tissue density
• high BMI (body mass index) 
• hormonal replacement therapy (HTR, especially E+PR)
At NCI website [13], a tool enabling to calculate the risk of 
breast cancer in an individual patient according to the risk 
factors present, so-called „BC RISK CALCULATOR”, can be 
found. Tab. 2 presents in 2 columns the examples of 2 dif-
ferent women with the risk of breast cancer calculated for 
either patient.
Additionally, it can be calculated that the risk of developing 
breast cancer by 90 years of age reaches even 44.8%, so it is 
4-fold higher than the mean risk in the population of white 
50-year-olds – 11.2%. 
Wang published in 2004 an important study [14], which 
indicates that the risk of developing breast cancer among 
women classified as category 1 or 2 – so-called LC-BBD 
(tab. 1) was 1.6-fold higher than in BBD-free population. On 
the basis of analysis of 11.307 women, including 1376 with 
LC-BBD (47 developed BC – 3.4%) and 9931 without LC-BBD 
(291 developed BC – 2.9%) the differences were assessed to 
be significant and independent of other risk factors (Gail 
model). Differences within the LC-BBD group were also 
compared by the author, who concluded that the relative 
risk (RR) of developing breast cancer among women with 
cyst-like breast lesions is 1.79 (95% CI 1.20-2.68) and is sig-
nificantly higher than in other non-cystic LC-BBD, where 
RR amounts to 1.42 (95% CI 0.91-1.95). Thus, a conclusion 
based on the study can be made that all BBD, and cysts in 
particular, significantly increase the risk of breast cancer. 
However, such conclusions can arouse considerable obje-
ctions, although they seem to be statistically correct. As it 
follows from the analyzed material, the risk of breast can-
cer among BBD-free women is 2.9%, among women with 
cysts 3.8% and among women with other types of LC-BBD 
3%. Thus, can we speak about a significant increase of risk 
in case of differences ranging from 0.1 to 0.9%?
Even more doubts arise when we look more closely at the 
material presented in this study which originates from … 
another study [15], published 6 years before (P1 – BREAST 
CANCER PREVENTION TRIAL) and concerning a ran-
domized clinical trial assessing prophylactic efficacy of 
tamoxifen in women with increased BC risk. The study 
analyzed 13,388 women (1992–97) with increased BC risk 
(RR>1.66%), receiving tamoxifen (6576) or placebo(6599). 
The results indicated that tamoxifen reduced almost by 
half the incidence of breast cancer, because 89 out of 6576 
women (1.4%) developed BC in that group in comparison 
with 175 BC cases in the control group of 6599 women 
Table 2. Example of breast cancer risk calculation in 2 women on the basis of risk factors – BC RISK CALCULATOR according to NCI.
 Risk factor Woman 1 Woman 2
History of breast cancer (including DCIS, LCIS) 
Age
Age at the menarche
Age at childbirth
1st degree relatives affected with breast cancer
Number of previous biopsies or surgical procedures 
Previous detection of atypical hyperplasia
Race
 NO
40
15
24 
0
0
NO
 
white 
NO
50
11
30
1
2
YES
white
CALCULATED BREAST CANCER RISK DURING 5-YEAR PERIOD:   0.6% 6.2% 
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(2.7%). That study led to appropriate recommendations for 
women with increased risk of breast cancer. However, it is 
a pity that so many women (98.7%) used (or still use) tamo-
xifen unnecessarily, because it provides favorable protecti-
ve effect only in 1.3% of the treated patients.
Coming back to Wang’s study, another important question 
arises: Can an additional risk factor be assessed (post fac-
tum) in a group of patients with generally increased risk? 
And should a study of 2004 have been based on material 
collected for a different purpose in 1992–97?
Other recent studies [16–20], suggesting a correlation 
between benign breast diseases and the occurrence of bre-
ast cancer, are even weaker in the methodological and sta-
tistical aspects. 
In turn, Hartmann [21] analyzed in in 2005 a group of 9087 
operated on for benign breast lesions (in 1967–91), among 
whom 707 (7.8%) developed breast cancer (10 years later, 
on the average, including 40% of cases in which the con-
tralateral breast was affected). The group, assessed with 
respect to age, relation to menopause and histological type 
of the lesion, was compared epidemiologically to the con-
trol population in Iowa. The resected lesions were divided 
into three histopathological types:
I – non-proliferative fibrocystic lesions – 67%, 
II – non-atypical proliferative fibrocystic lesions – 30% and 
III – atypical ductal or lobular hyperplasia – 4%.
The breast cancer risk for all lesion types was estimated to 
be 1.56-fold higher than in the control population (group 
I = 1.27, II = 1.88, III = 4.24). However, the authors 
emphasize that mastopathic lesions (group I, II) in patients 
 without high familial risk (mother or sister below 50 years 
of age or two women in the family including one next of 
kin) did not increase the frequency of breast cancer. 
These problems have also been assessed from another 
point of view [22] by Collins (a case-control study). On the 
basis of 2005 women with BBD including 395 (19.7%) who 
 developed breast cancer, the effect of positive family histo-
ry (FH+) on breast cancer risk according to the histological 
type of previously removed lesion (classified as above) was 
assessed. In comparison with type I BBD without positive 
family history, the risk of developing breast cancer was: 
1.51 for type II BBD FH-, 2.45 for type II BBD FH+, 4.38 
for type III BBD FH- and 5.37 for type III BBD FH+. Thus, 
positive family history slightly but significantly increased 
the risk of breast cancer for type II BBD and insignificantly 
increased the risk of breast cancer for type III BBD. 
Chun [23], on the basis of 1317 women with high breast 
cancer risk (including 28% with large cyst-like lesions) did 
not confirm the hypothesis that the presence of cysts in the 
breast is a significant risk factor for developing breast can-
cer [23]. 
Conclusion
It cannot be excluded that fibrocystic lesions increase the 
risk of breast cancer. Such influence, even if existing inde-
pendently of other risk factors, is fortunately low. Despite 
the publication of reports [24] concerning favorable effect 
of aspirin (by cyclooxygenase inhibition) on reducing the 
risk of breast cancer in women with benign breast diseases 
(mastopathy and/or BBD), further studies are necessary to 
elucidate potential correlations (and, first of all, their mag-
nitude) between the incidence of mastopathy and breast 
cancer.
The aim of such studies should be comparative analy-
sis of molecular, pathological, hormonal, biochemical and 
 imaging investigations in a group of patients with mastopa-
thy (only) and in a group with coincident mastopathy and 
breast cancer. The analysis of results should answer the 
following questions:
How frequent are mutations in the analyzed groups? 
What are the characteristic features of mastopathy and 
breast cancer in the analyzed examinations?
What examinations can be predictive of breast cancer in 
mastopathy?
What should be the algorithm of mastopathy management?
Systematic knowledge and standardization of management 
in benign breast diseases should result in economic ben-
efits, and indentification of women with high risk of breast 
cancer would allow early detection and most effective 
treatment. 
Unfortunately, KBN (Polish Scientific Research Committee) 
did not approve in 2004 a multicenter study designed to 
assess objective correlations between mastopathic lesions 
and breast cancer (1500 patients – PLN 1,5 m = 0.1% of all 
costs incurred by mastopathy).
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